vTv Therapeutics (VTVT) Competitors

$37.70 +6.03 (+19.03%)

As of 02:44 PM Eastern

VTVT vs. ENGN, UPB, ZURA, IMMX, and FDMT

Should you buy vTv Therapeutics stock or one of its competitors? MarketBeat compares vTv Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with vTv Therapeutics include enGene (ENGN), Upstream Bio (UPB), Zura Bio (ZURA), Immix Biopharma (IMMX), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

How does vTv Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

vTv Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A

64.2% of enGene shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 10.4% of enGene shares are owned by insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, enGene had 22 more articles in the media than vTv Therapeutics. MarketBeat recorded 29 mentions for enGene and 7 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.97 beat enGene's score of -0.52 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Negative
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

enGene's return on equity of -55.83% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
vTv Therapeutics	N/A	-73.76%	-43.53%

enGene presently has a consensus target price of $12.68, suggesting a potential upside of 629.26%. vTv Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 40.59%. Given enGene's higher possible upside, research analysts plainly believe enGene is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

enGene beats vTv Therapeutics on 7 of the 13 factors compared between the two stocks.

How does vTv Therapeutics compare to Upstream Bio?

vTv Therapeutics (NASDAQ:VTVT) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

vTv Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, vTv Therapeutics had 3 more articles in the media than Upstream Bio. MarketBeat recorded 7 mentions for vTv Therapeutics and 4 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.31 beat vTv Therapeutics' score of 0.97 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 40.59%. Upstream Bio has a consensus price target of $38.75, suggesting a potential upside of 352.05%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

vTv Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -5,026.03%. Upstream Bio's return on equity of -36.48% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-73.76%	-43.53%
Upstream Bio	-5,026.03%	-36.48%	-35.38%

vTv Therapeutics has higher earnings, but lower revenue than Upstream Bio. vTv Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A
Upstream Bio	$2.85M	163.68	-$143.44M	-$2.67	N/A

Summary

Upstream Bio beats vTv Therapeutics on 9 of the 15 factors compared between the two stocks.

How does vTv Therapeutics compare to Zura Bio?

Zura Bio (NASDAQ:ZURA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Zura Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

vTv Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A

Zura Bio's return on equity of -55.74% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
vTv Therapeutics	N/A	-73.76%	-43.53%

61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, vTv Therapeutics had 3 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for vTv Therapeutics and 4 mentions for Zura Bio. vTv Therapeutics' average media sentiment score of 0.97 beat Zura Bio's score of 0.16 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zura Bio presently has a consensus price target of $10.75, suggesting a potential upside of 123.08%. vTv Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 40.59%. Given Zura Bio's higher probable upside, equities research analysts plainly believe Zura Bio is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Zura Bio beats vTv Therapeutics on 7 of the 13 factors compared between the two stocks.

How does vTv Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Immix Biopharma's return on equity of -73.24% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
vTv Therapeutics	N/A	-73.76%	-43.53%

Immix Biopharma has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, vTv Therapeutics had 4 more articles in the media than Immix Biopharma. MarketBeat recorded 7 mentions for vTv Therapeutics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.36 beat vTv Therapeutics' score of 0.97 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 30.3% of Immix Biopharma shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

vTv Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A

Immix Biopharma currently has a consensus price target of $18.25, indicating a potential upside of 77.01%. vTv Therapeutics has a consensus price target of $53.00, indicating a potential upside of 40.59%. Given Immix Biopharma's higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

vTv Therapeutics beats Immix Biopharma on 8 of the 13 factors compared between the two stocks.

How does vTv Therapeutics compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

4D Molecular Therapeutics presently has a consensus target price of $29.88, indicating a potential upside of 202.78%. vTv Therapeutics has a consensus target price of $53.00, indicating a potential upside of 40.59%. Given 4D Molecular Therapeutics' higher probable upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

4D Molecular Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

vTv Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
vTv Therapeutics	N/A	-73.76%	-43.53%

In the previous week, 4D Molecular Therapeutics had 10 more articles in the media than vTv Therapeutics. MarketBeat recorded 17 mentions for 4D Molecular Therapeutics and 7 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.97 beat 4D Molecular Therapeutics' score of 0.19 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
vTv Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	6.05	-$140.11M	-$2.57	N/A
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A

Summary

4D Molecular Therapeutics beats vTv Therapeutics on 11 of the 14 factors compared between the two stocks.

Get vTv Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTVT vs. The Competition

Export

Metric	vTv Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$147.89M	$3.40B	$6.29B	$12.48B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-11.21	18.81	20.91	25.60
Price / Sales	N/A	284.65	548.78	75.41
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.30	6.78	9.87	6.72
Net Income	-$26.97M	$24.11M	$3.55B	$333.73M
7 Day Performance	21.45%	0.22%	-0.24%	0.38%
1 Month Performance	-1.65%	1.08%	1.44%	4.02%
1 Year Performance	76.90%	78.09%	41.01%	36.37%

vTv Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTVT vTv Therapeutics	2.8258 of 5 stars	$37.70 +19.0%	$53.00 +40.6%	+52.3%	$147.89M	N/A	N/A	9	News Coverage Earnings Report Gap Up High Trading Volume
ENGN enGene	3.2991 of 5 stars	$7.89 +3.7%	$22.69 +187.5%	-46.5%	$509.75M	N/A	N/A	31	Analyst Forecast Analyst Revision
UPB Upstream Bio	2.418 of 5 stars	$9.12 -2.0%	$39.00 +327.6%	+8.2%	$506.65M	$2.85M	N/A	38	News Coverage Positive News Earnings Report Analyst Forecast
ZURA Zura Bio	2.881 of 5 stars	$5.18 -2.6%	$10.75 +107.5%	+296.7%	$504.77M	N/A	N/A	3	Earnings Report
IMMX Immix Biopharma	2.9163 of 5 stars	$9.56 +0.8%	$18.25 +90.9%	+429.8%	$502.55M	N/A	N/A	9	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTVT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

vTv Therapeutics (VTVT) Competitors

VTVT vs. ENGN, UPB, ZURA, IMMX, and FDMT

How does vTv Therapeutics compare to enGene?

Summary

How does vTv Therapeutics compare to Upstream Bio?

Summary

How does vTv Therapeutics compare to Zura Bio?

Summary

How does vTv Therapeutics compare to Immix Biopharma?

Summary

How does vTv Therapeutics compare to 4D Molecular Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

vTv Therapeutics (VTVT) Competitors

VTVT vs. ENGN, UPB, ZURA, IMMX, and FDMT

How does vTv Therapeutics compare to enGene?

Which has higher valuation & earnings, ENGN or VTVT?

Do institutionals and insiders hold more shares of ENGN or VTVT?

Does the media prefer ENGN or VTVT?

Which has more risk and volatility, ENGN or VTVT?

Is ENGN or VTVT more profitable?

Do analysts rate ENGN or VTVT?

Summary

How does vTv Therapeutics compare to Upstream Bio?

Which has more risk & volatility, VTVT or UPB?

Do insiders & institutionals hold more shares of VTVT or UPB?

Does the media prefer VTVT or UPB?

Do analysts prefer VTVT or UPB?

Is VTVT or UPB more profitable?

Which has preferable valuation & earnings, VTVT or UPB?

Summary

How does vTv Therapeutics compare to Zura Bio?

Which has more risk and volatility, ZURA or VTVT?

Which has preferable earnings and valuation, ZURA or VTVT?

Is ZURA or VTVT more profitable?

Do insiders and institutionals hold more shares of ZURA or VTVT?

Does the media favor ZURA or VTVT?

Do analysts prefer ZURA or VTVT?

Summary

How does vTv Therapeutics compare to Immix Biopharma?

Is IMMX or VTVT more profitable?

Which has more volatility and risk, IMMX or VTVT?

Does the media refer more to IMMX or VTVT?

Do institutionals and insiders have more ownership in IMMX or VTVT?

Which has stronger earnings and valuation, IMMX or VTVT?

Do analysts recommend IMMX or VTVT?

Summary

How does vTv Therapeutics compare to 4D Molecular Therapeutics?

Do analysts recommend FDMT or VTVT?

Which has more risk & volatility, FDMT or VTVT?

Do insiders and institutionals have more ownership in FDMT or VTVT?

Is FDMT or VTVT more profitable?

Does the media favor FDMT or VTVT?

Which has higher valuation & earnings, FDMT or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTVT vs. The Competition

vTv Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools